Cover Image
市場調查報告書

激素敏感型前列腺癌 - 開發中產品分析

Hormone-Sensitive Prostate Cancer - Pipeline Review, H2 2014

出版商 Global Markets Direct 商品編碼 317358
出版日期 內容資訊 英文 36 Pages
訂單完成後即時交付
價格
Back to Top
激素敏感型前列腺癌 - 開發中產品分析 Hormone-Sensitive Prostate Cancer - Pipeline Review, H2 2014
出版日期: 2014年10月25日 內容資訊: 英文 36 Pages
簡介

激素敏感型前列腺癌是對男性荷爾蒙的睪酮(睪丸激素)水準變化敏銳度高的前列腺癌,發病要素有年齡,遺傳,荷爾蒙的水準,前列腺的發炎等。症狀為排尿困難,血尿,骨盆領域的不協調感,腰部,臀部,大腿部的疼痛,骨痛及勃起功能障礙等。治療方法有化療,放射線治療,及外科手術等。

本報告提供激素敏感型前列腺癌的治療藥開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

目錄

簡介

激素敏感型前列腺癌概要

治療藥的開發

  • 開發中產品:概要
  • 開發中產品:比較分析

開發中的治療藥:各企業

調查中的治療藥:各大學/實驗室

開發中產品的概要

  • 臨床階段的產品
  • 初期階段的產品

開發中的產品:各企業

調查中的產品:各大學/實驗室

治療藥的開發企業

  • Ipsen S.A.
  • Ultimovacs AS

治療藥的評估

  • 單獨療法的產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • Peptide Based Therapeutic Cancer Vaccine
  • Vaccine to Target Prostate Specific Antigen for Hormone-Sensitive Prostate Cancer
  • STX-2171
  • MVI-118
  • Small Molecules to Inhibit AKR1C3 for Oncology

開發中產品的最新趨勢

暫停中的計劃

開發中止的產品

產品開發的里程碑

  • 關註資訊和新聞稿

附錄

圖表

目錄
Product Code: GMDHC5638IDB

Summary

Global Markets Direct's, 'Hormone-Sensitive Prostate Cancer - Pipeline Review, H2 2014', provides an overview of the Hormone-Sensitive Prostate Cancer's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Hormone-Sensitive Prostate Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hormone-Sensitive Prostate Cancer and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Hormone-Sensitive Prostate Cancer
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Hormone-Sensitive Prostate Cancer and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Hormone-Sensitive Prostate Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Hormone-Sensitive Prostate Cancer pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Hormone-Sensitive Prostate Cancer
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Hormone-Sensitive Prostate Cancer pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Hormone-Sensitive Prostate Cancer Overview
  • Therapeutics Development
    • Pipeline Products for Hormone-Sensitive Prostate Cancer - Overview
    • Pipeline Products for Hormone-Sensitive Prostate Cancer - Comparative Analysis
  • Hormone-Sensitive Prostate Cancer - Therapeutics under Development by Companies
  • Hormone-Sensitive Prostate Cancer - Therapeutics under Investigation by Universities/Institutes
  • Hormone-Sensitive Prostate Cancer - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Hormone-Sensitive Prostate Cancer - Products under Development by Companies
  • Hormone-Sensitive Prostate Cancer - Products under Investigation by Universities/Institutes
  • Hormone-Sensitive Prostate Cancer - Companies Involved in Therapeutics Development
    • Ipsen S.A.
    • Ultimovacs AS
  • Hormone-Sensitive Prostate Cancer - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • Peptide Based Therapeutic Cancer Vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Vaccine to Target Prostate Specific Antigen for Hormone-Sensitive Prostate Cancer - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • STX-2171 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MVI-118 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit AKR1C3 for Oncology - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Hormone-Sensitive Prostate Cancer - Recent Pipeline Updates
  • Hormone-Sensitive Prostate Cancer - Dormant Projects
  • Hormone-Sensitive Prostate Cancer - Discontinued Products
  • Hormone-Sensitive Prostate Cancer - Product Development Milestones
    • Featured News & Press Releases
      • Apr 15, 2014: UK NICE guidance recommends FIRMAGON (degarelix) for the treatment of advanced hormone-dependent prostate cancer only in people with spinal metastases who present with signs or symptoms of impending spinal cord compression
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Hormone-Sensitive Prostate Cancer, H2 2014
  • Number of Products under Development for Hormone-Sensitive Prostate Cancer - Comparative Analysis, H2 2014
  • Number of Products under Development by Companies, H2 2014
  • Number of Products under Investigation by Universities/Institutes, H2 2014
  • Comparative Analysis by Clinical Stage Development, H2 2014
  • Comparative Analysis by Early Stage Development, H2 2014
  • Products under Development by Companies, H2 2014
  • Products under Investigation by Universities/Institutes, H2 2014
  • Hormone-Sensitive Prostate Cancer - Pipeline by Ipsen S.A., H2 2014
  • Hormone-Sensitive Prostate Cancer - Pipeline by Ultimovacs AS, H2 2014
  • Assessment by Monotherapy Products, H2 2014
  • Number of Products by Stage and Target, H2 2014
  • Number of Products by Stage and Mechanism of Action, H2 2014
  • Number of Products by Stage and Route of Administration, H2 2014
  • Number of Products by Stage and Molecule Type, H2 2014
  • Hormone-Sensitive Prostate Cancer Therapeutics - Recent Pipeline Updates, H2 2014
  • Hormone-Sensitive Prostate Cancer - Dormant Projects, H2 2014
  • Hormone-Sensitive Prostate Cancer - Discontinued Products, H2 2014

List of Figures

  • Number of Products under Development for Hormone-Sensitive Prostate Cancer, H2 2014
  • Number of Products under Development for Hormone-Sensitive Prostate Cancer - Comparative Analysis, H2 2014
  • Number of Products under Development by Companies, H2 2014
  • Number of Products under Investigation by Universities/Institutes, H2 2014
  • Comparative Analysis by Clinical Stage Development, H2 2014
  • Comparative Analysis by Early Stage Products, H2 2014
  • Assessment by Monotherapy Products, H2 2014
  • Number of Products by Top 10 Target, H2 2014
  • Number of Products by Stage and Top 10 Target, H2 2014
  • Number of Products by Top 10 Mechanism of Action, H2 2014
  • Number of Products by Stage and Top 10 Mechanism of Action, H2 2014
  • Number of Products by Top 10 Route of Administration, H2 2014
  • Number of Products by Stage and Top 10 Route of Administration, H2 2014
  • Number of Products by Top 10 Molecule Type, H2 2014
  • Number of Products by Stage and Top 10 Molecule Type, H2 2014
Back to Top